Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy
Abstract Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug deliver...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | Bioengineering & Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/btm2.10482 |